文献速递心血管胸部MRUS

心脏磁共振在心脏结节病诊断与预后中对常规筛查的补充作用

Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2017-03-15

321例活检证实的结节病患者接受常规心脏检查及心脏磁共振(CMR)晚期钆增强(LGE)并随访。按心脏节律学会共识标准29.9%诊断为心脏结节病,CMR曲线下面积0.984为最敏感和特异检查,LGE是主要终点独立预测因子(HR 5.68)。超声心动图筛查敏感性低(27.1%)。

要点

  • CMR的LGE是主要终点独立预测因子(HR 5.68,95%CI 1.74–18.49,p=0.004)。
  • CMR检出44例有症状和/或心电图异常但超声正常者及15例无症状基线正常者。
  • 超声心动图阳性预测值83.9%但敏感性仅27.1%,异常者仍可能需CMR确认。

核心结论

  • 在普通结节病人群中,CMR是诊断和预后心脏结节病最有价值的心脏检查;超声心动图作为筛查试验整体诊断价值有限,异常结果虽阳性预测值高但仍可能需CMR确认。

研究设计与样本

  • 321例活检证实的结节病患者接受常规心脏检查和CMR(含LGE),并按主要终点(全因死亡、持续性室性心动过速发作或心力衰竭住院的复合终点)和次要终点(非持续性室性心动过速发作)随访。

关键影像表现/征象

  • CMR检出44例有心脏症状和/或心电图异常但超声心动图正常的患者。
  • CMR检出15例无症状且基线检查正常的患者。
  • LGE是主要终点的独立预测因子(HR 5.68,95%CI 1.74–18.49,p=0.004)。
  • 在有心脏症状和/或心电图异常的患者中,CMR独立预测主要终点(HR 12.71,95%CI 1.48–109.35,p=0.021)。

诊断标准与关键数值

  • 按心脏节律学会共识标准,29.9%的患者诊断为心脏结节病。
  • CMR曲线下面积0.984,为最敏感和特异的检查。
  • 超声心动图在心脏病史和心电图基础上加入未改变初始筛查策略的敏感性(68.8% vs 72.9%)。
  • 超声心动图阳性预测值83.9%,敏感性27.1%。

临床应用与阅片要点

  • 在有心脏症状和/或心电图异常的结节病患者中,CMR可提高诊断准确性并独立预测主要终点。
  • 超声心动图筛查异常者,尽管阳性预测值高,仍可能需CMR确认。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The goal of this study was to assess the independent and collective diagnostic value of various modalities in cardiac sarcoidosis, delineate the role of cardiac magnetic resonance (CMR), and identify patients at risk.

BACKGROUND: Cardiac sarcoidosis is associated with increased morbidity and mortality. CMR is a key modality in the evaluation of patients with cardiac symptoms, but the complementary role of CMR to conventional tests for the diagnosis of cardiac sarcoidosis is not fully defined.

METHODS: Patients (N = 321) with biopsy-proven sarcoidosis underwent conventional cardiac testing and CMR with late gadolinium enhancement (LGE) and were followed up for primary (composite of all-cause mortality, sustained ventricular tachycardia [VT] episodes, or hospitalization for heart failure) and secondary (nonsustained VT episodes) endpoints.

RESULTS: Cardiac sarcoidosis was diagnosed in 29.9% of patients according to the Heart Rhythm Society consensus criteria. CMR was the most sensitive and specific test (area under the curve: 0.984); it detected 44 patients with cardiac symptoms and/or electrocardiogram (ECG) abnormalities but normal echocardiogram, as well as 15 asymptomatic patients with normal baseline testing. Echocardiography added to cardiac history and ECG did not change sensitivity of the initial screening strategy (68.8% vs. 72.9%). Despite a high positive predictive value (83.9%), echocardiography had a low sensitivity (27.1%). During follow-up, 7.2% of patients reached the primary endpoint and another 3.4% reached the secondary endpoint. LGE was and independent predictor of primary endpoints (hazard ratio: 5.68; 95% CI: 1.74 to 18.49; p = 0.004). LGE, age, and baseline nonsustained VT were independent predictors of all events. In patients with cardiac symptoms and/or an abnormal ECG, CMR increased diagnostic accuracy and independently predicted primary endpoints (hazard ratio: 12.71; 95% confidence interval: 1.48 to 109.35; p = 0.021).

CONCLUSIONS: Of all cardiac tests, CMR was the most valuable in the diagnosis and prognosis of cardiac sarcoidosis in a general sarcoidosis population. Echocardiography had an overall limited diagnostic value as a screening test, and an abnormal study, despite a high positive predictive value, may still need confirmation with CMR.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Kouranos V, Tzelepis GE, Rapti A, et al. Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017. PMID: 28330653. doi:10.1016/j.jcmg.2016.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。